Early in 2014, the U.S. Food and Drug Administration approved tiludronate for intravenous administration in horses with navicular disease. Despite being a relatively new drug used in veterinary medicine, some equine practitioners are already prescribing tiludronate for “off-label” use in horses with other conditions, such as osteoarthritis by injecting the drug directly into the joint rather than using a systemic route of administration.
Read complete article
Discover more from Ebarrelracing.com
Subscribe to get the latest posts sent to your email.
